HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.

Abstract
In the therapy using a combination of pegylated interferon-α and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC), approximately 50% of CHC patients infected with high viremia of HCV genotype 1 reached sustained viral response. The recent discovery revealed by a genome-wide association study technology provides the unexpected role of IL28B and inosine triphosphatase (ITPA) in HCV infection. The former single nucleotide polymorphisms (SNPs) around the IL28B gene could improve the diagnostics on the prediction of spontaneous clearance and the response to anti-HCV treatment, suggesting that these findings could be strong evidence to enhance the development of a novel therapeutic strategy and the basic study of IFN-λs. Interestingly, the discovered IL28B SNPs revealed the enigma that the viral clearance rate was dependent on ethnicity. The latter functional SNP in ITPA locus was the most significant SNP associated with RBV-induced anemia as well as IFN-induced thrombocytopenia. Note that severe Hb decline, which is mainly found in ITPA-CC patients, was inversely correlated with platelet reduction, contributing to an association between severe anemia and relative reactive increase in platelet count. These data may provide a valuable pharmacogenetic diagnostic tool for tailoring PEG-IFN/RBV dosing to minimize drug-induced adverse events and for further optimization of clinical anti-HCV chemotherapeutics.
AuthorsYasuhito Tanaka
JournalDigestion (Digestion) Vol. 84 Suppl 1 Pg. 50-5 ( 2011) ISSN: 1421-9867 [Electronic] Switzerland
PMID22156486 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2011 S. Karger AG, Basel.
Chemical References
  • Antiviral Agents
  • IFNL3 protein, human
  • Interleukins
  • Interferons
  • Pyrophosphatases
  • inosine triphosphatase
Topics
  • Antiviral Agents (therapeutic use)
  • Drug Therapy, Combination
  • Hepacivirus (isolation & purification)
  • Hepatitis C, Chronic (drug therapy, genetics)
  • Humans
  • Interferons
  • Interleukins (genetics)
  • Polymorphism, Single Nucleotide (genetics)
  • Pyrophosphatases (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: